MYELODYSPLASTIC SYNDROME WITH EXCESS BLASTS
Clinical trials for MYELODYSPLASTIC SYNDROME WITH EXCESS BLASTS explained in plain language.
Never miss a new study
Get alerted when new MYELODYSPLASTIC SYNDROME WITH EXCESS BLASTS trials appear
Sign up with your email to follow new studies for MYELODYSPLASTIC SYNDROME WITH EXCESS BLASTS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
First human trial launches for experimental blood cancer treatment
Disease control Recruiting nowThis early-stage study is testing a new drug called APL-4098 to see if it's safe and effective for adults with advanced forms of blood cancer that have returned or stopped responding to other treatments. Researchers will give APL-4098 alone and in combination with two standard ca…
Matched conditions: MYELODYSPLASTIC SYNDROME WITH EXCESS BLASTS
Phase: PHASE1 • Sponsor: Apollo Therapeutics Ltd • Aim: Disease control
Last updated Apr 03, 2026 14:43 UTC
-
Targeted radiation and transplant tested as lifeline for tough blood cancers
Disease control Recruiting nowThis study is testing a new treatment for adults with high-risk or hard-to-treat blood cancers like leukemia. The treatment involves a radioactive antibody designed to target cancer cells, followed by a stem cell transplant from a partially matched family donor. The main goals ar…
Matched conditions: MYELODYSPLASTIC SYNDROME WITH EXCESS BLASTS
Phase: PHASE1, PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Apr 03, 2026 14:42 UTC
-
New drug combo targets genetic driver in High-Risk blood disorders
Disease control Recruiting nowThis study is testing whether a drug called enasidenib, sometimes combined with another drug called azacitidine, can help control high-risk myelodysplastic syndrome (MDS) in patients who have a specific genetic mutation called IDH2. The trial includes 63 patients who either haven…
Matched conditions: MYELODYSPLASTIC SYNDROME WITH EXCESS BLASTS
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Apr 03, 2026 14:41 UTC
-
New drug enters first human trial for Tough-to-Treat leukemias
Disease control Recruiting nowThis is a first-in-human study to find a safe dose and understand the side effects of an experimental drug called TAK-243. It is for adults with acute myeloid leukemia or myelodysplastic syndromes that have returned or not responded to prior treatments. The drug is given by IV an…
Matched conditions: MYELODYSPLASTIC SYNDROME WITH EXCESS BLASTS
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New drug cocktail tested to fight aggressive blood cancers
Disease control Recruiting nowThis study is testing a combination of five drugs to treat adults newly diagnosed with specific, aggressive forms of blood cancer. The goal is to see if this combination is safe and effective at putting the cancer into remission. The treatment involves chemotherapy and a targeted…
Matched conditions: MYELODYSPLASTIC SYNDROME WITH EXCESS BLASTS
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
New 'Smart Bomb' radiation therapy tested for Tough-to-Treat leukemias
Disease control Recruiting nowThis study is testing a new experimental drug that delivers radiation directly to cancer cells in patients with high-risk blood cancers like acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). The goal is to find the safest and most effective dose of this targete…
Matched conditions: MYELODYSPLASTIC SYNDROME WITH EXCESS BLASTS
Phase: PHASE1, PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
Custom immune cells fight blood cancers after transplant
Disease control Recruiting nowThis study tests a personalized immune cell therapy for patients with blood cancers like leukemia, lymphoma, and myeloma. After receiving chemotherapy and a cord blood transplant, patients get infusions of natural killer (NK) cells—immune cells that may kill remaining cancer cell…
Matched conditions: MYELODYSPLASTIC SYNDROME WITH EXCESS BLASTS
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 23, 2026 15:18 UTC